Universal reference book for medicines
Product name: FAMCICLOVIR-TEVA (FAMCICLOVIR-TEVA)

Active substance: famciclovir

Type: Antiviral drug

Manufacturer: Teva Pharmaceutical Industries (Israel) manufactured by NOVOPHARM (Canada)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

PHARMACHOLOGIC EFFECT
An antiviral agent.
After oral administration, famciclovir in vivo rapidly turns into penciclovir, which has in vivo and in vitro activity against human herpesviruses, including the Varicella zoster and Herpes simplex virus types 1 and 2, as well as the Epstein-Barr virus and cytomegalovirus.
Penzyclovir enters the virus-infected cells, where, under the action of the viral thymidine kinase, it rapidly converts to monophosphate, which in turn, with the participation of cellular enzymes, turns into triphosphate.
Penciclovir triphosphate is found in virus-infected cells for more than 12 hours, suppressing the synthesis of viral DNA and the replication of viruses. The half-life of penciclovir triphosphate in cells affected by Varicella zoster, Herpes simplex, is 9, 10 and 20 hours, respectively. The concentration of penciclovir triphosphate in uninfected cells does not exceed the minimum determined, therefore in therapeutic concentrations penciclovir does not affect uninfected cells.
Penciclovir is active against recently detected aciclovir-resistant strains of the Herpes simplex virus with altered DNA polymerase.

Famciclovir significantly reduces the intensity and duration of postherpetic neuralgia in patients with herpes zoster.

In a placebo-controlled study in patients with immunodeficiency due to HIV infection, famciclovir 500 mg 2 times / day reduced the number of days of Herpes simplex virus isolation (both with and without clinical manifestations).

PHARMACOKINETICS
After oral administration, famciclovir is rapidly and almost completely absorbed and rapidly converted to active penciclovir.
Bioavailability of penciclovir after oral administration of famciclovir is 77%. At doses of famciclovir 125 mg, 250 mg or 500 mg C max of penciclovir is achieved on average 45 minutes.
At repeated receptions of a preparation of a cumulation it is not noted.
The binding to plasma proteins of penciclovir and its 6-deoxy precursor is less than 20%.
T 1/2 of penciclovir from the plasma in the final phase after taking single and repeated doses is about 2 hours.

Famciclovir is excreted mainly in the form of penciclovir and its 6-deoxy progenitor, which are excreted in the urine unchanged;
famciclovir in the urine is not detected.
INDICATIONS
Infections caused by the Varicella zoster virus (shingles, including shingles with eye complications);
infections caused by the Herpes simplex virus (primary infection, exacerbation of chronic infection, suppression of recurrent infection).
DOSING MODE
Treatment should be started immediately after diagnosis.

When administered orally, a single dose of 250-500 mg.
The frequency and duration of application depend on the indications, the state of immunity, the function of the kidneys, the effectiveness of the treatment.
SIDE EFFECT
Possible: mild and moderate headaches, nausea.

Rarely: vomiting, dizziness, skin rash;
mainly in elderly patients - confusion, hallucinations.
In patients with reduced immunity: abdominal pain, fever;
rarely - granulocytopenia and thrombocytopenia.
CONTRAINDICATIONS
Hypersensitivity to famciclovir and penciclovir.

PREGNANCY AND LACTATION
Since the safety of famciclovir during pregnancy and during lactation has not been studied, use is not recommended unless the expected benefit of therapy for the mother exceeds the potential risk to the fetus or infant.

It is not known whether penciclovir is excreted in human milk.

Famciclovir does not have a pronounced effect on spermogram, morphology or motility of human spermatozoa.

In experimental studies, embryotoxic and teratogenic effects of famciclovir and penciclovir have not been revealed.

Studies on rats treated with famciclovir inward showed that penciclovir is excreted in breast milk.

A decrease in fertility was noted in the experimental model in male rats receiving famciclovir at a dose of 500 mg / kg of body weight, in female rats a pronounced decrease in fertility was not observed.

APPLICATION FOR FUNCTIONS OF THE LIVER
Use with caution in patients with impaired renal function.

SPECIAL INSTRUCTIONS
Use with caution in patients with impaired renal function.

In the presence of clinical manifestations of genital herpes even in the case of the initiation of antiviral treatment, patients should avoid sexual contact.

DRUG INTERACTION
Probenecid and other drugs that affect the function of the kidneys can change the level of penciclovir in the plasma.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!